Cargando…
Alternative Therapy and Abnormal Liver Function During Adjuvant Chemotherapy in Breast Cancer Patients
Although hepatotoxicity has been rarely reported during adjuvant chemotherapy in breast cancer patients, we observed a high frequency in our patients who were also taking alternative agents. We therefore sought to determine the association between hepatotoxicity and alternative agents during adjuvan...
Autores principales: | Ahn, Jin-Hee, Kim, Sung-Bae, Yun, Mi Ra, Lee, Jung-Shin, Kang, Yoon-Koo, Kim, Woo Kun |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816841/ https://www.ncbi.nlm.nih.gov/pubmed/15201506 http://dx.doi.org/10.3346/jkms.2004.19.3.397 |
Ejemplares similares
-
Hepatitis B Reactivation During Adjuvant Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Single Institution's Experience
por: Kim, Min Kyoung, et al.
Publicado: (2007) -
ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015) -
Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004) -
Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis
por: Cha, Yoon Jin, et al.
Publicado: (2022) -
T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy
por: An, Min Sung, et al.
Publicado: (2015)